-
Migraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies Headache (IF 5.0) Pub Date : 2024-03-13 Irina Krikova, Kathleen B. Digre, Bradley J. Katz, Meagan D. Seay, Judith E.A. Warner
Plain language summaryIdiopathic intracranial hypertension (IIH) is a condition of high pressure in the spinal fluid that is common in young women who are overweight or obese. Headache happens in most individuals with IIH and can continue after the early phase of IIH has resolved. We studied the use of a newer type of medication developed for migraine called calcitonin gene‐related peptide antibodies
-
Predictors and concomitants of the remission of frequent headache in pediatrics: A longitudinal community study Headache (IF 5.0) Pub Date : 2024-03-05 Lisa‐Marie Rau, Clarissa Humberg, Anna Könning, Benedikt B. Claus, Lorin Stahlschmidt, Julia Wager
ObjectiveWe aimed to examine factors associated with frequent headache remission in schoolchildren aged 10–18 years.BackgroundFrequent headache is a common health problem in adolescence, and some individuals in this population experience remission. Factors preceding headache remission as opposed to ongoing headache, and their development over time, have not been examined extensively.MethodsData were
-
Comparison of migraine with left‐ versus right‐sided headache: A cross‐sectional study Headache (IF 5.0) Pub Date : 2024-03-04 Adam S. Sprouse Blum, Lauren A. DaSilva, Michael D. Greenberg, Alexander J. Nissenbaum, Robert E. Shapiro, Benjamin Littenberg
ObjectiveThe goal of this study was to clarify whether clinical differences exist between patients with migraine who experience headache that is typically left‐sided (“left‐migraine”) versus right‐sided (“right‐migraine”) during attacks.BackgroundMigraine has been associated with unilateral headache for millennia and remains a supportive trait for the clinical diagnosis of migraine of the International
-
Low pulse pressure and high serum complement C1q are risk factors for hemodialysis headache: A case–control study Headache (IF 5.0) Pub Date : 2024-03-02 Quan Gan, Lily Zhang, Yuting Fang, Liu Yang, Ming Shi, Zheman Xiao
Background and ObjectiveHemodialysis headache (HDH) is a common complication of dialysis that negatively affects the patient's quality of life. The etiology and triggering factors of HDH are not fully understood. This study aims to assess the prevalence and characteristics of HDH among patients undergoing hemodialysis across multiple centers in China. Furthermore, we conducted a case–control study
-
Cerebrovascular reactivity to hypercapnia in patients with migraine: A dual‐echo arterial spin labeling MRI study Headache (IF 5.0) Pub Date : 2024-03-02 E. S. Hoogeveen, N. Pelzer, E. Ghariq, M. J. P. van Osch, A. Dahan, G. M. Terwindt, M. C. Kruit
ObjectiveThis study aimed to compare cerebrovascular reactivity between patients with migraine and controls using state‐of‐the‐art magnetic resonance imaging (MRI) techniques.BackgroundMigraine is associated with an increased risk of cerebrovascular disease, but the underlying mechanisms are still not fully understood. Impaired cerebrovascular reactivity has been proposed as a link. Previous studies
-
A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults Headache (IF 5.0) Pub Date : 2024-02-28 Richard B. Lipton, Detlef Albrecht, Maria Bermudez, Jerry Hu, Elizabeth Hussey, Jeff Levy
ObjectiveTo compare the safety and pharmacokinetics (PK) of dihydroergotamine (DHE) after administration of intranasal DHE powder (STS101), liquid nasal spray (LNS) DHE mesylate, and intramuscular (IM) DHE mesylate injection in healthy participants.BackgroundDHE is an effective acute migraine treatment; however, self‐administration difficulties have prevented its broader role in the management of migraine
-
Characteristics of acute ischemic stroke and unusual aura in patients with migraine with aura Headache (IF 5.0) Pub Date : 2024-02-28 Adrian Scutelnic, Nathalie L. Sutter, Morin Beyeler, Thomas R. Meinel, Franz Riederer, Urs Fischer, Marcel Arnold, Heinrich P. Mattle, Simon Jung, Christoph J. Schankin
BackgroundSometimes migraine aura changes from attack to attack, raising the question of whether the change is heralding an ischemic stroke or an unusual aura. Differentiating unusual migraine aura from the onset of an acute ischemic stroke in patients with migraine with aura (MwA) can be challenging.ObjectiveThe aim of this cohort study was to assess clinical characteristics that help distinguish
-
Beyond myths: Transformative insights into spinal cerebrospinal fluid leaks and their role in persistent headache syndromes Headache (IF 5.0) Pub Date : 2024-02-22 Ian Carroll, Andrew L. Callen
The last decade has seen a significant improvement in the understanding of spinal cerebrospinal fluid (CSF) leaks and the resulting syndrome of spontaneous intracranial hypotension (SIH). For the reader of Headache and those caring for patients with chronic refractory headaches, three novel concepts are emerging from accumulating data published here and elsewhere: (1) the majority of people with an
-
Long-term outcomes of Gamma Knife radiosurgery in treating glossopharyngeal neuralgia Headache (IF 5.0) Pub Date : 2024-02-22 Yavuz Samanci, Elif Mürdün, Mahmut Çil, Ali Haluk Düzkalir, Mehmet Orbay Askeroglu, Selcuk Peker
Glossopharyngeal neuralgia (GPN) is an unusual disorder causing severe, brief pain episodes in the areas supplied by the glossopharyngeal nerve. Initial treatment involves medications like carbamazepine, but if these are ineffective or cause side effects, interventional pain management techniques or surgery may be considered. Gamma Knife radiosurgery is becoming popular in managing GPN due to its lower
-
Blood pressure elevation in erenumab‐treated patients with migraine: A retrospective real‐world experience Headache (IF 5.0) Pub Date : 2024-02-27 Nikita Chhabra, Carolyn Mead‐Harvey, Christopher A. Dodoo, Courtney Iser, Hallie Taylor, Hira Chaudhary, Aimen Vanood, David W. Dodick
BackgroundErenumab is a monoclonal antibody that targets the calcitonin gene‐related peptide (CGRP) receptor and is approved for the preventative treatment of migraine in adults. CGRP is involved in the regulation of vasomotor tone under physiologic and pathologic conditions, including hypertension. While there has not been evidence of hypertension in preclinical models or clinical trials, post‐marketing
-
Correction to: “Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial” Headache (IF 5.0) Pub Date : 2024-02-26
Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman JM. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial. Headache. 2023 Jan;63(1):79-88. https://doi.org/10.1111/head.14439 The NCT number cited in the second sentence of the Methods section was incorrect
-
Synergistic effect of combining dual enkephalinase inhibitor PL37 and sumatriptan in a preclinical model of migraine Headache (IF 5.0) Pub Date : 2024-02-22 Jeanne Rossignol, Tanja Ouimet, Hervé Poras, Radhouane Dallel, Philippe Luccarini
ObjectiveThe aim of this study was to test whether a combination of sumatriptan with dual enkephalinase inhibitor PL37 would result in an additive or a synergistic effect.BackgroundCombination treatment is frequently used to improve the therapeutic efficacy of drugs. The co‐administration of two drugs may result in efficacy at lower doses than those needed for either drug alone, thus minimizing side
-
Anti‐neutrophil cytoplasmic antibody‐associated vasculitis with headache and stroke as the main symptoms: A case report Headache (IF 5.0) Pub Date : 2024-02-22 Xiaoyu Wu, Xiao Liu, Le Liu, Xiangqi Cao, Mengyuan Zhang, Sifan Wang, Meiying Deng, Guogang Luo, Qiumin Qu, Yitong Bian, Fude Liu, Jing Luo, Suhang Shang
CASE PRESENTATION A 64-year-old male with a nearly 40-year history of migraine (2–6 attacks/month, lasting up to 1 day each time, symptoms relieved with oral nonsteroidal anti-inflammatory drugs [NSAIDs]) visited the Neurology Department due to intermittent low-grade fever for 6 months, numbness in the left limb for 55 days, and persistent headache for 50 days. On approximately Day −180 (for convenience
-
Reviewer acknowledgment 2023 Headache (IF 5.0) Pub Date : 2024-02-02 Jenn Vallimont
CONFLICT OF INTEREST STATEMENT Jenn Vallimont receives payment from the American Headache Society for her role as Managing Editor of Headache.
-
Substance use in a Dutch migraine cohort compared with the general population Headache (IF 5.0) Pub Date : 2024-02-01 Thomas C. van den Hoek, Iris E. Verhagen, Irene de Boer, Gisela M. Terwindt
To evaluate self-reported substance user profiles for individuals with migraine and compare these to the general population.
-
Screen time and pediatric headache: A scoping review of the literature Headache (IF 5.0) Pub Date : 2024-02-01 Raquel L. Langdon, Marc T. DiSabella, Jeffrey A. Strelzik
The aim of this study was to summarize the evidence regarding screen use as a contributing factor in pediatric headache and migraine.
-
Regulation of headache response and transcriptomic network by the trigeminal ganglion clock Headache (IF 5.0) Pub Date : 2024-01-30 Chorong Han, Ji Ye Lim, Nobuya Koike, Sun Young Kim, Kaori Ono, Celia K. Tran, Elizaveta Mangutov, Eunju Kim, Yanping Zhang, Lingyong Li, Amynah A. Pradhan, Kazuhiro Yagita, Zheng Chen, Seung-Hee Yoo, Mark J. Burish
To characterize the circadian features of the trigeminal ganglion in a mouse model of headache.
-
Daith piercing: Revisited from the perspective of auricular acupuncture systems. A narrative review Headache (IF 5.0) Pub Date : 2024-01-29 Saroj K. Pradhan, Andreas R. Gantenbein, Yiming Li, Hamdy Shaban, Xiaoying Lyu, Ahmet Sevik, Michael Furian
Daith piercing is a special ear-piercing method that punctures the crus of the helix. The penetrated site at the ear's innermost point is assumed to stimulate a pressure point associated with the vagus nerve. It has been reported that the pierced spot relieves migraine and tension-type headaches by activating vagal afferents, leading to the inhibition of neurons in the caudal trigeminal nucleus via
-
Effect of prednisolone for the treatment of medication-overuse headache: A 3-month result from a multicenter REgistry for Load and management of mEdicAtion overuSE headache (RELEASE) study Headache (IF 5.0) Pub Date : 2024-01-29 Mi Ji Lee, Hong-Kyun Park, Sun-Young Oh, Jin-Ju Kang, Yooha Hong, Heui-Soo Moon, Tae-Jin Song, Min Kyung Chu, Soo-Jin Cho
To evaluate the efficacy of prednisolone in the treatment of medication-overuse headache (MOH) using data from a multicenter prospective registry (Registry for Load and Management of Medication Overuse Headache [RELEASE]).
-
Neuromodulation for primary headache disorders: Advantages and challenges Headache (IF 5.0) Pub Date : 2024-01-29 Crystal Jicha, Kendra Pham
CONFLICT OF INTEREST STATEMENT Crystal Jicha declares no conflicts of interest. Kendra Pham declares no conflicts of interest.
-
Metaphorical use of “headache” and “migraine” in media: A longitudinal study of 1.3 million articles in major publications Headache (IF 5.0) Pub Date : 2024-01-18 Pengfei Zhang, Advika Ventrapragada, Robert E. Shapiro, Thien Phu Do
Stigmatization and trivialization of headache confront individuals with headache disorders, but the degree to which media may contribute is incompletely understood.
-
The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine Headache (IF 5.0) Pub Date : 2024-01-18 Rikki Mangrum, Alexandra L. Bryant, Maya T. Gerstein, Kelly P. McCarrier, Carrie R. Houts, James S. McGinley, Dawn C. Buse, Richard B. Lipton, R. J. Wirth
To describe the impact of migraine on functioning based on comprehensive data collection, analysis, and reporting of patients' experiences.
-
Examining substance use patterns in adults with migraine: A changing landscape Headache (IF 5.0) Pub Date : 2024-01-18 Angeliki Vgontzas
CONFLICT OF INTEREST STATEMENT Angeliki Vgontzas declares no conflict of interest.
-
Epidemiology and clinical features of paroxysmal hemicrania: A systematic review and meta-analysis Headache (IF 5.0) Pub Date : 2024-01-11 Mikkel J. Henningsen, Johanne G. Larsen, William K. Karlsson, Rune H. Christensen, Haidar M. Al-Khazali, Faisal Mohammad Amin, Håkan Ashina
To assess the prevalence or relative frequency of paroxysmal hemicrania and its clinical features in the adult general population and among adult patients evaluated for headache in tertiary care.
-
Bone site fracture pain after subcutaneous sumatriptan injection: A report of two cases Headache (IF 5.0) Pub Date : 2023-12-29 Marion Beltramone, Sylvain Redon, Anne Donnet
CONFLICT OF INTEREST STATEMENT Dr. Beltramone declares no conflicts of interest. Dr. Redon has received consulting fees from Teva and AbbVie. Dr. Donnet has received consulting fees or served on the advisory board for Allergan/AbbVie, Lilly, Lundbeck, Novartis, Pfizer, and Teva.
-
Biomarkers in cluster headache: A systematic review Headache (IF 5.0) Pub Date : 2023-12-18 Marie-Louise K. Søborg, Rigmor H. Jensen, Mads Barloese, Anja S. Petersen
To systematically investigate previously examined biomarkers in blood, urine, cerebrospinal fluid, tear fluid, and saliva of patients with cluster headache.
-
Rural disparities in emergency department utilization for migraine care Headache (IF 5.0) Pub Date : 2023-12-12 Christian Rhudy, Aric Schadler, Mark Huffmyer, Lindsey Porter
To evaluate differences in emergency department (ED) utilization and quality of care for migraine in patients with rural and nonrural residences.
-
Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study Headache (IF 5.0) Pub Date : 2023-12-10 Bruce A. Chase, Irene Semenov, Susan Rubin, Steven Meyers, Angela Mark, Thomas Makhlouf, Tanya T. Chirayil, Demetrius Maraganore, Jun Wei, Siqun L. Zheng, Jianfeng Xu, Alexander Epshteyn, Anna Pham, Roberta Frigerio, Katerina Markopoulou
To evaluate response to anti-calcitonin gene–related peptide (CGRP) migraine preventives in a real-world community cohort of persons living with migraine and to identify clinical and genetic characteristics associated with efficacious response.
-
Reduction in retinal microvascular perfusion during migraine attacks Headache (IF 5.0) Pub Date : 2023-11-30 Katherine Podraza, Nitin Bangera, Akira Feliz, Andrew Charles
To determine if there are changes in structure and function of the retinal vasculature during and between migraine attacks using optical coherence tomography angiography (OCTA).
-
Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE-1 and EVOLVE-2 Headache (IF 5.0) Pub Date : 2023-11-28 E. Anne MacGregor, Rose Okonkwo, Holland C. Detke, Pepa Polavieja, Maria S. Fernandes, Jelena M. Pavlovic
We evaluated galcanezumab for migraine prevention in patients who met International Classification of Headache Disorders, 3rd edition criteria for menstrually related migraine (MRM).
-
NINDS Common Data Elements for post-traumatic headache: A project from the American Headache Society Post-Traumatic Headache Special Interest Section Headache (IF 5.0) Pub Date : 2023-11-27 Catherine D. Chong, Sait Ashina, Joshua Kamins, Ann Scher, Carlyn Patterson Gentile, Alan Finkel, Michael L. Oshinsky, Todd J. Schwedt
CONFLICT OF INTEREST STATEMENT Catherine D. Chong has received research funding from the American Heart Association, Amgen, National Institutes of Health, and United States Department of Defense. Sait Ashina has been a consultant for Abbvie/Allergan, Amgen, Biohaven, Eli Lilly, Novartis, Pfizer, Supernus, Teva, Theranica, Percept, and Impel Neuropharma. Joshua Kamins serves on the speaker bureau for
-
Patient headache questionnaires can improve headache diagnosis and treatment in children Headache (IF 5.0) Pub Date : 2023-11-17 Christina L. Szperka, Stephanie Witzman, Svetlana Ostapenko, John T. Farrar, Jesse Yenchih Hsu, Carrie P. Malavolta, Janille D. Bunney, Erin M. Bange, Carlyn Patterson Gentile, Gerardo Velasquez, Blanca Marquez de Prado, Mahgenn Cosico, Meyeon Lee, Pamela Pojomovsky McDonnell, Marisa S. Prelack, Madeline A. Chadehumbe, Donna J. Stephenson, Elizabeth A. Kichula, Scott C. Tomaine, Andrew D. Hershey
To examine trends in diagnosis of headache and migraine in a large pediatric neurology cohort, and test whether an electronic health record (EHR)-integrated headache questionnaire can increase specificity of diagnosis and likelihood of prescribing migraine treatment.
-
Patient headache questionnaires can improve headache diagnosis and treatment in children Headache (IF 5.0) Pub Date : 2023-11-14 Christina L. Szperka
Linked article: https://onlinelibrary.wiley.com/doi/full/10.1111/head.14645
-
Headache launches the publication of plain language summaries Headache (IF 5.0) Pub Date : 2023-11-14 Jenn Vallimont, Robert C. Gibler, Amy A. Gelfand
Plain Language Summary Publication: https://onlinelibrary.wiley.com/doi/full/10.1111/head.14647
-
Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis Headache (IF 5.0) Pub Date : 2023-11-13 Messoud Ashina, Dimos D. Mitsikostas, Verena Ramirez Campos, Steve Barash, Xiaoping Ning, Hans-Christoph Diener
This study aimed to determine the number needed to treat (NNT), number needed to harm (NNH), and likelihood of being helped or harmed (LHH) in a post hoc analysis of the phase 3b FOCUS trial.
-
Association between secondhand smoke exposure and severe headaches or migraine in never-smoking adults Headache (IF 5.0) Pub Date : 2023-11-08 Junpeng Wu, Panpan Yang, Xiaodan Wu, Xiaoxuan Yu, Fanfang Zeng, Haitang Wang
The study aimed to examine the relationship between secondhand smoke (SHS) exposure and severe headaches or migraine in never-smoking adults verified by serum cotinine.
-
Trainee highlights Headache (IF 5.0) Pub Date : 2023-11-08 Sarah M. Bobker
CONFLICT OF INTEREST STATEMENT Dr. Sarah M. Bobker volunteers her time as an Associate Editor at Headache where she also manages the journal's Instagram account and serves as Course Director for Headache's Assistant Editor Team Program. She has no personal or financial disclosures.
-
A qualitative study on the long-term effectiveness of occipital nerve stimulation in patients with chronic cluster headache Headache (IF 5.0) Pub Date : 2023-11-07 E. Kurt, R. W. Volkers, Y. Engels, W. M. Mulleners, R. L. Witkam, R. T. M. van Dongen
INTRODUCTION Cluster headache (CH) is a headache disorder that greatly incapacitates patients and leads to a considerable negative impact on their well-being, the ability to perform daily activities or work, social functioning, and quality of life (QoL).1, 2 About 15% of patients with CH have no proper response to medication, in which case it is labeled as “medically intractable chronic cluster headache”
-
The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis Headache (IF 5.0) Pub Date : 2023-10-26 Leon S. Moskatel, Anna Graber-Naidich, Zihuai He, Niushen Zhang
To determine the effect of the introduction of the calcitonin gene–related peptide monoclonal antibodies (CGRP mAbs) in 2018 on the prescribing of older medications for the prevention of chronic migraine.
-
Understanding the links between airborne hazards and headache disorders Headache (IF 5.0) Pub Date : 2023-10-26 Elizabeth K. Seng, Andrea H. Weinberger
CONFLICT OF INTEREST STATEMENT Dr. Elizabeth K. Seng has received consulting fees or served on the advisory board for GlaxoSmithKline, Abbvie, and Theranica. She has received research funding from the Veterans Health Administration, the National Institutes of Health, and the American Heart Association. Dr. Andrea H. Weinberger has no conflicts to report.
-
Hypermobility spectrum disorders and migraine in adolescents Headache (IF 5.0) Pub Date : 2023-10-24 Chia-Chun Chiang
CONFLICT OF INTEREST STATEMENT In the prior 24 months, Chia-Chun Chiang has received personal compensation for consulting with Satsuma and eNeura. She also receives research support from American Heart Association with grants paid to her institution.
-
Caution regarding fabricated citations from artificial intelligence Headache (IF 5.0) Pub Date : 2023-10-24 Fred Cohen, Jenn Vallimont, Amy A. Gelfand
CONFLICT OF INTEREST STATEMENT Dr. Fred Cohen serves as an assistant editor for Headache. In the last 24 months, Dr. Cohen has received honoraria from Current Pain and Headache Reports. Ms. Jenn Vallimont receives payment from the American Headache Society for her role as managing editor of Headache. In the last 24 months, Dr. Amy A. Gelfand has received honoraria from UpToDate (for authorship) and
-
Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials Headache (IF 5.0) Pub Date : 2023-10-24 Charlie J. Iaconangelo, Daniel Serrano, Aubrey Manack Adams, Joel M. Trugman, Richard B. Lipton
To evaluate an alternative method of defining acute treatment success in migraine by combining multiple indicators into a single dichotomous measure of success.
-
Comparative prevalence and characteristics of fabricated citations in large language models in headache medicine Headache (IF 5.0) Pub Date : 2023-10-14 Leon S. Moskatel, Niushen Zhang
CONFLICT OF INTEREST STATEMENT Leon S. Moskatel and Niushen Zhang declare no conflicts of interest.
-
Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy Headache (IF 5.0) Pub Date : 2023-10-13 Giulia Hyeraci, Olga Paoletti, Luigi Francesco Iannone, Rosa Gini, Francesco De Cesaris, Pierangelo Geppetti, Giuseppe Roberto
To describe the pattern of anti-calcitonin gene–related peptide monoclonal antibodies (anti-CGRP mAbs) utilization in the Tuscany region, Italy, and the variation of triptan consumption after treatment initiation.
-
Plasma calcitonin gene–related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion Headache (IF 5.0) Pub Date : 2023-10-05 Ann I. Scher, James S. McGinley, Lyndsey R. VanDam, Amanda M. Campbell, Xiyun Chai, Billy Collins, Scott A. Klimp, Alan G. Finkel, Karen Schwab, Richard B. Lipton, Kirk W. Johnson
The objective of this study was to characterize the utility of calcitonin gene–related peptide (CGRP) and nerve growth factor (NGF) as potential biomarkers for headache and pain disorders in the post–military deployment setting.
-
Impact of monthly headache days on migraine-related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study Headache (IF 5.0) Pub Date : 2023-10-05 Richard B. Lipton, Patricia Pozo-Rosich, Serena L. Orr, Michael L. Reed, Kristina M. Fanning, Brett Dabruzzo, Dawn C. Buse
To characterize the direct impact of monthly headache days (MHDs) on health-related quality of life (HRQoL) in people with migraine and the potential mediating effects of anxiety, depression, and allodynia.
-
Migraine and air pollution: A systematic review Headache (IF 5.0) Pub Date : 2023-10-05 Andrea E. Portt, Christa Orchard, Hong Chen, Erjia Ge, Christine Lay, Peter M. Smith
To systematically synthesize evidence from a broad range of studies on the association between air pollution and migraine.
-
Headache and psychological variables as predictors of disability in individuals with primary headache disorders Headache (IF 5.0) Pub Date : 2023-10-05 Halle T. McCracken, Aaron A. Lee, Todd A. Smitherman
To examine the relative contribution of headache symptoms and psychological factors to headache-related disability.
-
Effects of caffeine on intracranial pressure and pain perception in freely moving rats Headache (IF 5.0) Pub Date : 2023-10-05 Ida Marchen Egerod Israelsen, Connar Stanley James Westgate, Christina Kamp-Jensen, Rigmor H. Jensen, Sajedeh Eftekhari
Caffeine, a non-selective adenosine receptor (AR) antagonist, is the most consumed psychostimulant in the world. Caffeine has been suggested to regulate cerebrospinal fluid secretion and is known both to alleviate and to trigger headache; however, its effect on the regulation of intracranial pressure (ICP) is not known. Therefore, we aimed to investigate the effects of caffeine on ICP and nociceptive
-
The 2023 Scottsdale Headache Symposium Headache (IF 5.0) Pub Date : 2023-10-05 Deborah I. Friedman, Rashmi B. Halker Singh, Scott W. Powers
CONFLICT OF INTEREST STATEMENT Deborah I. Friedman, Rashmi B. Halker Singh, and Scott W. Powers declare no conflicts of interest.
-
Neuropathic changes in corneal nerve endings—A potential objective biomarker for migraine frequency and response to treatment Headache (IF 5.0) Pub Date : 2023-09-23 Nur Amalina Md Isa, Shyam S. Tummanapalli, Jeremy Chung Bo Chiang, Arun V. Krishnan, Alessandro S. Zagami, Eric B. Papas, Maria Markoulli, Katherine Spira
The cornea is one of the most densely innervated structures in the body, mainly supplied by sensory fibers from the ophthalmic division of the trigeminal nerve—a key player in migraine pathophysiology.1 Previous studies have demonstrated variable differences in the corneal nerve morphology of patients with migraine2-4; therefore, the cornea could represent a potential window into migraine pathophysiology
-
Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study Headache (IF 5.0) Pub Date : 2023-09-23 Victor S. Wang, Justin Kosman, Hsiangkuo Yuan, Clinton Lauritsen, Stephen Shrewsbury, Sheena K. Aurora, Mary Hopkins, Stephen Silberstein
Dihydroergotamine (DHE), like triptans, is contraindicated in patients with ischemic heart disease or coronary vasospasm. Its true safety, tolerability, and efficacy in patients with cardiovascular risk without ischemic heart disease or coronary vasospasm remain unclear.
-
Correction to “Regional cerebral perfusion during the premonitory phase of triggered migraine: A double-blind randomized placebo-controlled functional imaging study using pseudo-continuous arterial spin labelling” Headache (IF 5.0) Pub Date : 2023-09-18
Karsan N, Bose RP, O'Daly O, Zelaya F, Goadsby PJ. Regional cerebral perfusion during the premonitory phase of triggered migraine: A double-blind randomized placebo-controlled functional imaging study using pseudo-continuous arterial spin labeling. Headache. 2023;63(6):771-787. https://doi.org/10.1111/head.14538 Page 772, paragraph 2 in ‘Imaging the premonitory phase’; ‘and these findings have been
-
Correction to “A causative role for remote dural puncture and resultant arachnoid bleb in new daily persistent headache: A case report” Headache (IF 5.0) Pub Date : 2023-09-18
Callen AL, Lennarson P, Carroll IR. A causative role for remote dural puncture and resultant arachnoid bleb in new daily persistent headache: A case report. Headache. 2023;63(7):981-983. https://doi.org/10.1111/head.14584 A colleague has brought to our attention an additional lumbar puncture in this patient's history that we include here for completeness. The updated relevant timeline should be understood
-
Changes in cognitive appraisal in a randomized controlled trial of mindfulness-based cognitive therapy for patients with migraine Headache (IF 5.0) Pub Date : 2023-09-18 Jessica A. Kruse, Elizabeth K. Seng
This study is a secondary analysis evaluating changes in cognitive fusion and pain catastrophizing over 8 weeks of mindfulness-based cognitive therapy for migraine (MBCT-M) intervention versus waitlist/treatment as usual.
-
Association between clinician specialty and prescription of preventive medication for young adults with migraine: A retrospective cohort study Headache (IF 5.0) Pub Date : 2023-09-11 Hannah F. J. Shapiro, Elizabeth Loder, Daniel J. Shapiro
We aimed to compare the prescribing patterns of preventive medications between pediatric and adult neurologists for young adults with migraine.
-
“Growing pains” in children and adolescents as an early symptom of migraine: A prospective study Headache (IF 5.0) Pub Date : 2023-09-06 Raimundo Pereira Silva-Néto, Adriana de Almeida Soares, Wallyson Pablo de Oliveira Souza, Ana Gabriela Krymchantowski, Carla Jevoux, Abouch Krymchantowski
Children and adolescents may experience pain in the lower limbs, predominantly at the end of the day or during the night, without any relation to organic disease. These pains are often called “growing pains” (GP) by pediatricians and orthopedists. They are commonly attributed to rapid growth.
-
Aura is a symptom of a migraine attack, not its cause Headache (IF 5.0) Pub Date : 2023-09-04 Andrew Charles
CONFLICT OF INTEREST STATEMENT Andrew Charles reports personal fees from Amgen, personal fees from Eli Lilly, personal fees from Lundbeck, personal fees from UCB Pharma, and personal fees from My Everyday Health outside the submitted work. He is president of the American Headache Society.
-
Association between migraine and cardiovascular disease mortality: A prospective population-based cohort study Headache (IF 5.0) Pub Date : 2023-09-01 Huanxian Liu, Shuhua Zhang, Zihua Gong, Wei Zhao, Xiaoxue Lin, Yingyuan Liu, Shengshu Wang, Shengyuan Yu, Zhao Dong
The study assessed the association between migraine and cardiovascular disease (CVD) mortality in the US population.